MA41315A - Composés co-agonistes de gip et de glp-1 - Google Patents

Composés co-agonistes de gip et de glp-1

Info

Publication number
MA41315A
MA41315A MA041315A MA41315A MA41315A MA 41315 A MA41315 A MA 41315A MA 041315 A MA041315 A MA 041315A MA 41315 A MA41315 A MA 41315A MA 41315 A MA41315 A MA 41315A
Authority
MA
Morocco
Prior art keywords
gip
glp
agonist compounds
compounds
incretinimetic
Prior art date
Application number
MA041315A
Other languages
English (en)
Other versions
MA41315B1 (fr
Inventor
Jorge Alsina-Fernandez
Bengt Krister Bokvist
Tamer Coskun
Robert Chadwick Cummins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55315708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41315(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA41315A publication Critical patent/MA41315A/fr
Publication of MA41315B1 publication Critical patent/MA41315B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des composés incrétino-mimétiques duels qui sont des agonistes des récepteurs humains à la fois du gip (glucose-dependent insulinotropic polypeptide) et du glp-1 (glucagon-like peptide-1), et qui peuvent être utilisés pour traiter le diabète sucré de type 2 (t2d).
MA41315A 2015-01-09 2016-01-05 Composés co-agonistes de gip et de glp-1 MA41315B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101488P 2015-01-09 2015-01-09
PCT/US2016/012124 WO2016111971A1 (fr) 2015-01-09 2016-01-05 Composés co-agonistes de gip et de glp-1

Publications (2)

Publication Number Publication Date
MA41315A true MA41315A (fr) 2017-11-15
MA41315B1 MA41315B1 (fr) 2019-11-29

Family

ID=55315708

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050422A MA50422A (fr) 2015-01-09 2016-01-05 Composés co-agonistes gip et glp-1
MA41315A MA41315B1 (fr) 2015-01-09 2016-01-05 Composés co-agonistes de gip et de glp-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA050422A MA50422A (fr) 2015-01-09 2016-01-05 Composés co-agonistes gip et glp-1

Country Status (45)

Country Link
US (1) US9474780B2 (fr)
EP (2) EP3242887B1 (fr)
JP (3) JP6219534B2 (fr)
KR (4) KR101957620B1 (fr)
CN (2) CN107207576B (fr)
AR (1) AR103242A1 (fr)
AU (1) AU2016205435B2 (fr)
CA (1) CA2973352C (fr)
CL (1) CL2017001760A1 (fr)
CO (1) CO2017006737A2 (fr)
CR (1) CR20170310A (fr)
CY (1) CY1122028T1 (fr)
DK (1) DK3242887T3 (fr)
DO (1) DOP2017000153A (fr)
EA (3) EA035055B1 (fr)
EC (1) ECSP17043648A (fr)
ES (1) ES2747928T3 (fr)
FI (1) FIC20230005I1 (fr)
FR (1) FR23C1006I2 (fr)
HR (1) HRP20191614T1 (fr)
HU (2) HUE045860T2 (fr)
IL (3) IL252499B (fr)
JO (2) JOP20200119A1 (fr)
LT (2) LT3242887T (fr)
MA (2) MA50422A (fr)
MD (1) MD3242887T2 (fr)
ME (1) ME03494B (fr)
MX (2) MX2017008927A (fr)
MY (1) MY193616A (fr)
NL (1) NL301217I2 (fr)
NO (1) NO2023005I1 (fr)
NZ (1) NZ732000A (fr)
PE (1) PE20170954A1 (fr)
PH (1) PH12017501252A1 (fr)
PL (1) PL3242887T3 (fr)
PT (1) PT3242887T (fr)
RS (1) RS59146B1 (fr)
SG (1) SG11201705603YA (fr)
SI (1) SI3242887T1 (fr)
SV (1) SV2017005453A (fr)
TN (1) TN2017000198A1 (fr)
TW (1) TWI582109B (fr)
UA (1) UA118239C2 (fr)
WO (1) WO2016111971A1 (fr)
ZA (1) ZA201703930B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3082797A4 (fr) 2013-12-18 2017-12-13 The California Institute for Biomedical Research Agents thérapeutiques modifiés, conjugués lipide-peptide agrafés, et compositions les comprenant
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2018104263A1 (fr) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'amélioration de l'activité de médicaments à base d'incrétine chez des sujets en ayant besoin
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
WO2018213151A1 (fr) * 2017-05-18 2018-11-22 Merck Sharp & Dohme Corp. Formulation pharmaceutique comprenant des conjugués d'incrétine-insuline
TWI809515B (zh) * 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019140030A1 (fr) * 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
MA52483A (fr) * 2018-05-04 2021-03-10 Novo Nordisk As Dérivés de gip et leurs utilisations
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
MA53390A (fr) * 2018-07-23 2021-06-02 Lilly Co Eli Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie
CN112469431A (zh) * 2018-07-23 2021-03-09 伊莱利利公司 使用gip/glp1共激动剂用于糖尿病的方法
AU2019311000B2 (en) * 2018-07-23 2023-02-02 Eli Lilly And Company GIP/GLP1 co-agonist compounds
JP6564539B1 (ja) 2018-09-14 2019-08-21 長瀬産業株式会社 スルホン酸化合物によるペプチド精製方法
US20220016215A1 (en) 2018-09-24 2022-01-20 Takeda Phaarmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
TWI799680B (zh) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
TWI764209B (zh) 2019-08-01 2022-05-11 美商美國禮來大藥廠 Gipr促效劑化合物
CA3148347A1 (fr) 2019-08-19 2021-02-25 Michael E. Kopach Procedes de fabrication d'analogues d'incretine
JP2022551282A (ja) 2019-10-04 2022-12-08 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
EP4093757A1 (fr) * 2020-01-23 2022-11-30 Eli Lilly and Company Composés co-agonistes de gip/glp1
TW202140058A (zh) * 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
EP4110800A1 (fr) 2020-03-06 2023-01-04 Sanofi Peptides servant d'agonistes sélectifs du récepteur gip
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
IL299707A (en) 2020-07-22 2023-03-01 Novo Nordisk As Co-agonists for GLP-1 and GIP receptors
CA3184717A1 (fr) * 2020-07-22 2022-01-27 Patrick J. KNERR Co-agonistes au niveau des recepteurs de glp-1 et de gip appropries pour une administration par voie orale
CN115925994B (zh) * 2020-09-30 2023-09-22 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
US20240020543A1 (en) 2020-10-17 2024-01-18 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
CA3200881A1 (fr) * 2020-12-02 2022-06-09 Zhixiang PAN Composes polypeptidiques modifies par lactame
WO2022159395A1 (fr) * 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions et procédés pour le traitement de troubles métaboliques et hépatiques
EP4294419A2 (fr) 2021-02-17 2023-12-27 Eli Lilly And Co. Méthodes thérapeutiques au tirzépatide
WO2022177744A1 (fr) * 2021-02-17 2022-08-25 Eli Lilly And Company Procédés thérapeutiques agonistes doubles gip/glp1
US20240150425A1 (en) * 2021-03-25 2024-05-09 Brightgene Bio-Medical Technology Co., Ltd. Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
US20240209056A1 (en) 2021-03-25 2024-06-27 Brightgene Bio-Medical Technology Co., Ltd. Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
WO2022235991A1 (fr) 2021-05-07 2022-11-10 Eli Lilly And Company Comprimé érodable
CN117866050A (zh) * 2021-05-28 2024-04-12 广东众生睿创生物科技有限公司 多肽的制备及其应用
WO2022253202A1 (fr) * 2021-06-01 2022-12-08 南京知和医药科技有限公司 Dérivé polypeptidique ayant un effet d'activation à double cible de glp-1r et de gipr, procédé de préparation associé et son utilisation
WO2022262825A1 (fr) * 2021-06-18 2022-12-22 南京明德新药研发有限公司 Composé polypeptidique contenant un pont lactame
CN118159552A (zh) 2021-09-06 2024-06-07 赛诺菲 作为强效的且选择性的gip受体激动剂的新肽
CA3231953A1 (fr) * 2021-09-15 2023-03-23 Brian Lian Compositions et methodes de traitement de troubles metaboliques et hepatiques
WO2023084118A1 (fr) 2021-11-15 2023-05-19 Adocia Compositions solides comprenant un peptide ou une protéine et un acide aminé acylé
EP4299057A1 (fr) 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
EP4180060A1 (fr) 2021-11-15 2023-05-17 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
WO2023089594A1 (fr) 2021-11-22 2023-05-25 Sun Pharmaceutical Industries Limited Procédé de préparation de tirzépatide ou de sel pharmaceutiquement acceptable de celui-ci
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023193727A1 (fr) * 2022-04-07 2023-10-12 广东众生睿创生物科技有限公司 Utilisation pharmaceutique de polypeptide dans la préparation de médicaments pour le traitement et/ou la prévention du diabète et de l'obésité et de maladies associées
WO2024006662A1 (fr) 2022-06-30 2024-01-04 Eli Lilly And Company Compositions de tirzepatide et leur utilisation
EP4299052A1 (fr) 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un agent améliorant la perméation
EP4299071A1 (fr) 2022-07-01 2024-01-03 Adocia Compositions comprenant un peptide ou une protéine et un acide aminé acylé
TW202411244A (zh) * 2022-07-13 2024-03-16 中國大陸商杭州中美華東製藥有限公司 Ｇｌｐ－１／ｇｉｐ雙激動劑及其製備方法和用途
WO2024020388A1 (fr) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Formulations pharmaceutiques et méthodes pour le traitement de troubles métaboliques et hépatiques
WO2024050289A1 (fr) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions pour administration orale
WO2024059674A1 (fr) * 2022-09-15 2024-03-21 Eli Lilly And Company Composés agonistes doubles de gip et de glp-1
WO2024061310A1 (fr) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 Composition pharmaceutique à base de double agoniste des récepteurs glp-1 et gip et utilisation correspondante
WO2024077149A2 (fr) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides pour la synthèse d'incrétine
WO2024098718A1 (fr) * 2022-11-07 2024-05-16 内蒙古博睿精创科技有限公司 Nouveau composé polypeptidique à action prolongée, composition et utilisation associée
WO2024112617A2 (fr) 2022-11-21 2024-05-30 Eli Lilly And Company Procédé de préparation d'un double agoniste gip/glp1
WO2024145638A2 (fr) 2022-12-29 2024-07-04 Eli Lilly And Company Procédés et intermédiaires pour la préparation de tirzépatide
WO2024141760A1 (fr) 2022-12-30 2024-07-04 Algipharma As Compositions et procédés pour augmenter la biodisponibilité systémique d'un agent thérapeutique polypeptidique subissant une administration orale
CN116832141B (zh) * 2023-06-06 2024-02-09 诺博泰科(成都)生物科技有限公司 一种用于治疗糖尿病的glp-1、gip和gcg受体三激动多肽化合物
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
ES2490243T3 (es) * 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US9072703B2 (en) * 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
RU2550696C2 (ru) 2008-12-19 2015-05-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Основанные на амидах пролекарства пептидов глюкагонового надсемейства
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
KR101091041B1 (ko) * 2010-07-29 2011-12-09 고려대학교 산학협력단 새로운 재조합 글루코스 의존성 인슐린분비 펩타이드(ｒｃＧＩＰ) 작용제 및 그 용도
ES2713952T3 (es) 2010-12-22 2019-05-24 Univ Indiana Res & Tech Corp Análogos de glucagón que muestran actividad de receptor de GIP
MX2013007327A (es) * 2010-12-22 2014-01-08 Marcadia Biotech Inc Metodos para tratar transtornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de gip y glp-1.
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
EP2718317B1 (fr) 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Analogues de polypeptides insulinotropes dépendants du glucose, compositions pharmaceutiques et son utilisation
WO2012171994A1 (fr) 2011-06-15 2012-12-20 Novo Nordisk A/S Insulines à substitutions multiples
IN2014CN02448A (fr) 2011-09-23 2015-06-19 Novo Nordisk As
KR20140114845A (ko) * 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
TWI599575B (zh) 2012-06-21 2017-09-21 印第安納大學科技研究公司 表現ｇｉｐ受體活性之胰高血糖素類似物
EP2908845A1 (fr) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance
RU2652783C2 (ru) 2012-12-21 2018-05-03 Санофи Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона
PT3004155T (pt) 2013-05-28 2021-12-22 Takeda Pharmaceuticals Co Composto peptídico

Also Published As

Publication number Publication date
JP2017507124A (ja) 2017-03-16
BR112017010596A2 (pt) 2018-03-06
SI3242887T1 (sl) 2019-10-30
EA201892057A1 (ru) 2019-02-28
NO2023005I1 (no) 2023-02-02
JOP20200119A1 (ar) 2017-06-16
CL2017001760A1 (es) 2018-03-16
SV2017005453A (es) 2018-08-27
MA41315B1 (fr) 2019-11-29
EA201791281A1 (ru) 2017-11-30
ES2747928T3 (es) 2020-03-12
IL252499B (en) 2020-08-31
HUE045860T2 (hu) 2020-01-28
FR23C1006I2 (fr) 2024-01-05
JP2019203000A (ja) 2019-11-28
TW201636362A (zh) 2016-10-16
MY193616A (en) 2022-10-20
AU2016205435B2 (en) 2018-03-29
KR20230023822A (ko) 2023-02-17
AU2016205435A1 (en) 2017-06-08
ZA201703930B (en) 2019-06-26
JP2018052933A (ja) 2018-04-05
NZ748274A (en) 2022-03-25
WO2016111971A1 (fr) 2016-07-14
DOP2017000153A (es) 2017-07-15
EA031591B1 (ru) 2019-01-31
JP6754867B2 (ja) 2020-09-16
UA118239C2 (uk) 2018-12-10
CN107207576B (zh) 2020-11-24
PE20170954A1 (es) 2017-07-13
KR20170092661A (ko) 2017-08-11
ME03494B (fr) 2020-01-20
JP6545766B2 (ja) 2019-07-17
NZ732000A (en) 2018-11-30
HUS2300006I1 (hu) 2023-02-28
CY1122028T1 (el) 2020-10-14
EA202090392A2 (ru) 2020-05-31
CO2017006737A2 (es) 2017-09-29
LT3242887T (lt) 2019-11-11
DK3242887T3 (da) 2019-09-02
KR20210145311A (ko) 2021-12-01
EP3597662A1 (fr) 2020-01-22
RS59146B1 (sr) 2019-09-30
PT3242887T (pt) 2019-10-29
EA202090392A3 (ru) 2020-08-31
IL281545A (en) 2021-05-31
EP3242887A1 (fr) 2017-11-15
TN2017000198A1 (en) 2018-10-19
CN112608377A (zh) 2021-04-06
IL276492A (en) 2020-09-30
KR20190026967A (ko) 2019-03-13
FIC20230005I1 (fi) 2023-02-02
CN107207576A (zh) 2017-09-26
MX2017008927A (es) 2017-10-11
EA035055B1 (ru) 2020-04-22
MX2021005835A (es) 2021-07-15
AR103242A1 (es) 2017-04-26
JP6219534B2 (ja) 2017-10-25
IL252499A0 (en) 2017-07-31
PL3242887T3 (pl) 2020-02-28
MD3242887T2 (ro) 2019-11-30
SG11201705603YA (en) 2017-08-30
EP3242887B1 (fr) 2019-08-14
NL301217I1 (fr) 2023-02-15
KR102330764B1 (ko) 2021-11-25
US9474780B2 (en) 2016-10-25
FR23C1006I1 (fr) 2023-03-24
JO3575B1 (ar) 2020-07-05
LTPA2023504I1 (fr) 2023-02-27
NL301217I2 (nl) 2023-04-04
ECSP17043648A (es) 2017-11-30
CN112608377B (zh) 2024-02-13
MA50422A (fr) 2020-08-26
CR20170310A (es) 2017-08-17
IL276492B (en) 2021-04-29
CA2973352C (fr) 2019-03-26
KR101957620B1 (ko) 2019-03-13
PH12017501252A1 (en) 2017-10-30
TWI582109B (zh) 2017-05-11
US20160199438A1 (en) 2016-07-14
CA2973352A1 (fr) 2016-07-14
HRP20191614T1 (hr) 2019-12-13

Similar Documents

Publication Publication Date Title
MA41315B1 (fr) Composés co-agonistes de gip et de glp-1
MY197569A (en) Gip/glp1 co-agonist compounds
SA518391903B1 (ar) معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي
DK3989972T3 (da) Glucagon-lignende peptid-1-receptor-agonister
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
IL279224B1 (en) 1-glp agonist receptors and their use
EA201690660A1 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
CR20220020A (es) Compuestos agonistas de gipr
MA46219A (fr) Composés de co-agonistes du glucagon et du glp-1
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
EA202191379A1 (ru) Комбинированное лечение nafld и nash
MX2015009433A (es) Polipeptidos novedosos que tienen actividad liberadora de hormonas de la saciedad.
EA202092891A1 (ru) Соединения-коагонисты gip/glp1